

(51) International Patent Classification:
C12Q 1/68 (2006.01)(21) International Application Number:
PCT/US2010/053334(22) International Filing Date:
20 October 2010 (20.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/253,758 21 October 2009 (21.10.2009) US(71) Applicant (for all designated States except US):
GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GRAHAM, Robert** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).(74) Agents: **KALINOWSKI, Grant** et al.; Genentech, Inc., 1 DNA Way, MS-49, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION

Figure 1: Mean change in Visual Acuity after 12 months of Lucentis® Therapy, stratified by the sum of risk alleles from the MMP25 (rs1064875), DDR2 (rs10917583) and BATF (rs175714) loci.



(57) Abstract: The application relates to methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.